サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1565654

クロストリジウム・ディフィシル感染症治療の世界市場：タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2024年～2032年）

Clostridium Difficile Infection Treatment Market, By Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
クロストリジウム・ディフィシル感染症治療の世界市場：タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、予測（2024年～2032年）
出版日: 2024年09月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

世界のクロストリジウム・ディフィシル感染症治療の市場規模は、2023年に8億9,690万米ドルとなり、2024年～2032年にCAGR7.90%で拡大すると予測されています。

クロストリジウム・ディフィシル感染症治療市場-市場力学

院内感染の増加により、クロストリジウム・ディフィシル感染治療ソリューションの需要が増加

院内感染（HAI）の増加により、クロストリジウム・ディフィシル感染症の効果的な治療に対するニーズが高まっています。米国疾病予防管理センター（CDC）によると、HAIは毎日病院患者の約31人に1人が罹患しており、中でもクロストリジウム・ディフィシルが最も一般的な原因菌の1つとなっています。2020年、CDCは米国だけでクロストリジウム・ディフィシルが22万3,900人近くの入院患者に感染を引き起こし、1万2,800人以上の死亡につながったと報告しました。HAIを減少させるヘルスケア機関の努力は、厳格な感染管理対策とともに、より高度で的を絞った治療の採用を促進しています。抗生物質耐性が懸念される中、糞便微生物叢移植（FMT）のような代替療法の開発は、これらの感染症と闘う広範な戦略の一環として勢いを増しています。

クロストリジウム・ディフィシル感染症治療市場-主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024年～2032年）に約7.90%のCAGRで毎年成長すると推定されています。

タイプ別では、抗生物質が2023年に最大の市場シェアを示すと予測されています。

投与経路別では、経口剤が2023年の主要タイプでした。

地域別では、北米が2023年の主要収益源でした。

クロストリジウム・ディフィシル感染症治療市場-セグメンテーション分析：

世界のクロストリジウム・ディフィシル感染症治療市場は、タイプ、投与経路、エンドユーザー、地域に基づいてセグメント化されます。

市場はタイプ別に4つのカテゴリーに分けられ、抗生物質、プロバイオティクス、糞便微生物叢移植（FMT）、モノクローナル抗体です。抗生物質は広く使用されているため、クロストリジウム・ディフィシル感染症治療市場を独占しており、次いで糞便微生物叢移植（FMT）が代替療法として勢いを増しています。モノクローナル抗体が台頭する一方で、プロバイオティクスが支持療法として注目されつつあります。

市場は投与経路によって3つのカテゴリーに分けられ、経口投与、静脈内投与、直腸投与です。経口投与は、簡便さと患者のコンプライアンスからクロストリジウム・ディフィシル治療に最も一般的であり、次いで重症例に使用される静脈内投与です。直腸投与はあまり一般的ではありませんが、糞便微生物叢移植（FMT）のような標的療法に用いられます。

クロストリジウム・ディフィシル感染症治療市場-地理的洞察

クロストリジウム・ディフィシル感染症治療市場は地域差が大きく、北米が感染率の高さと強固なヘルスケアインフラによりリードしています。CDCは、米国ではクロストリジウム・ディフィシルが年間1万2,800人近い死亡の原因となっていると推定しており、公衆衛生の取り組みにおいて重要な焦点となっています。欧州もこれに続き、欧州疾病予防管理センター（ECDC）がHAIの報告義務化など厳格な感染管理対策を実施しており、市場の成長に拍車をかけています。アジア太平洋は、特に日本や中国のような国々で、意識の高まりと診断能力の向上を目の当たりにしています。2021年、日本の厚生省は抗菌薬耐性を減らすためのイニシアチブを開始し、CDI（クロストリジウム・ディフィシル感染症）治療の需要に直接影響を与えています。ラテンアメリカと中東・アフリカは、先進的な治療法の導入は遅れているものの、感染率の上昇と医療制度の強化に向けた取り組みが原動力となり、ヘルスケアへの投資が増加しています。これらの地域では、革新的な治療へのアクセスが徐々に改善されつつあり、将来的な市場の可能性が生まれています。

クロストリジウム・ディフィシル感染症治療市場-競合情勢：

クロストリジウム・ディフィシル感染症治療市場は競争が激しく、主要企業は提携、買収、薬剤革新などの戦略的イニシアティブに注力しています。Merck & Co., Inc.やFerring Pharmaceuticalsなどの主要企業が市場の最前線にいます。メルクのDIFICID（R）（フィダキソマイシン）は依然として主要な治療選択肢であり、2022年にはBiomedical Advanced Research and Development Authority（BARDA）との提携を発表し、次世代治療法を模索しています。フェリング・ファーマシューティカルズはRebiotix, Inc.の買収で注目を集め、CDIに対する先駆的な糞便微生物叢移植（FMT）療法であるFDA承認のREBYOTA（R）を含む微生物に基づく療法の開発を加速させています。ファイザーも、2021年に後期臨床試験に入ったクロストリジウム・ディフィシルワクチンの候補に取り組み、躍進しています。このような戦略的な動きは、CDIの世界の負担の増大に対処するために、大手企業が競合するだけでなく、協力し、将来の成長と革新のために自らを位置づけていることを示しています。

目次

第1章 クロストリジウム・ディフィシル感染症治療市場の概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 クロストリジウム・ディフィシル感染症治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 クロストリジウム・ディフィシル感染症治療産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 クロストリジウム・ディフィシル感染症治療市場：COVID-19の影響分析

  • COVID-19前の影響分析
  • COVID-19後の影響分析

第6章 クロストリジウム・ディフィシル感染症治療市場の情勢

  • クロストリジウム・ディフィシル感染症治療市場シェア分析：2023年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 クロストリジウム・ディフィシル感染症治療市場- タイプ別

  • 概要
    • セグメントシェア分析：タイプ別
    • 抗生物質
    • プロバイオティクス
    • 糞便微生物叢移植（FMT）
    • モノクローナル抗体

第8章 クロストリジウム・ディフィシル感染症治療市場- 投与経路別

  • 概要
    • セグメントシェア分析：投与経路別
    • 経口
    • 静脈内
    • 直腸

第9章 クロストリジウム・ディフィシル感染症治療市場- エンドユーザー別

  • 概要
    • セグメントシェア分析：エンドユーザー別
    • 病院
    • クリニック
    • 長期介護施設
    • 在宅医療環境

第10章 クロストリジウム・ディフィシル感染症治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- クロストリジウム・ディフィシル感染症治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Acurx Pharmaceuticals, Inc.
    • Da Volterra
    • Ferring Pharmaceuticals Inc.
    • Finch Therapeutics Group, Inc.
    • Immuron Ltd.
    • Johnson &Johnson Services, Inc.
    • Maat Pharma SA
    • Merck &Co., Inc.
    • Microbiotica Ltd.
    • Pfizer Inc.
    • Prokaryotics Inc.
    • Rebiotix Inc.（a Ferring company）
    • Sanofi SA
    • Seres Therapeutics, Inc.
    • Summit Therapeutics plc
    • Vedanta Biosciences, Inc.
    • その他

第12章 アナリストの全方位展望

目次
Product Code: ANV3813

REPORT HIGHLIGHT

Clostridium Difficile Infection Treatment Market size was valued at USD 896.90 Million in 2023, expanding at a CAGR of 7.90% from 2024 to 2032.

The Clostridium Difficile Infection (CDI) Treatment Market focuses on therapeutic solutions to combat infections caused by the Clostridium difficile bacterium, which leads to severe diarrhea and inflammation of the colon. The rising incidence of hospital-acquired infections, coupled with the increasing use of broad-spectrum antibiotics, has fueled the demand for effective CDI treatments. Innovative drug developments, such as microbiome therapeutics and monoclonal antibodies, are reshaping the market landscape. Regulatory challenges, particularly in drug approval pathways, act as barriers to market growth. However, with over 450,000 cases of CDI reported annually in the U.S. alone, there is significant opportunity for the development of novel treatment solutions. In addition, the growing awareness of antimicrobial resistance highlights the need for safer and more targeted treatment options, opening avenues for companies to invest in next-generation therapies.

Clostridium Difficile Infection Treatment Market- Market Dynamics

Rising Incidence of Hospital-Acquired Infections Boosts Demand for Clostridium Difficile Infection Treatment Solutions

The increasing prevalence of hospital-acquired infections (HAIs) has intensified the need for effective treatments for Clostridium Difficile infections. According to the Centers for Disease Control and Prevention (CDC), HAIs affect approximately 1 in 31 hospital patients daily, with Clostridium Difficile being one of the most common culprits. In 2020, the CDC reported that C. difficile caused nearly 223,900 infections in hospitalized patients in the U.S. alone, leading to over 12,800 deaths. Efforts by healthcare institutions to reduce HAIs, along with stringent infection control measures, are driving the adoption of more advanced and targeted treatments. With ongoing concerns about antibiotic resistance, the development of alternative therapies, such as fecal microbiota transplants (FMT), has gained momentum as part of a broader strategy to combat these infections.

Clostridium Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.90% over the forecast period (2024-2032)

Based on Type segmentation, Antibiotics was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridium Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridium Difficile Infection Treatment Market is segmented on the basis of Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Type: Antibiotics, Probiotics, Fecal Microbiota Transplantation (FMT), and Monoclonal Antibodies. Antibiotics dominate the Clostridium Difficile Infection Treatment Market due to their widespread use, followed by Fecal Microbiota Transplantation (FMT) gaining momentum as an alternative therapy. Monoclonal antibodies are emerging, while probiotics are seeing increasing attention as supportive treatments.

The market is divided into three categories based on the Route of Administration: Oral, Intravenous, and Rectal. Oral administration is the most common for Clostridium difficile treatments due to ease and patient compliance, followed by intravenous administration, which is used for severe cases. Rectal administration is less common but utilized for targeted therapies like Fecal Microbiota Transplantation (FMT).

Clostridium Difficile Infection Treatment Market- Geographical Insights

The Clostridium Difficile Infection Treatment Market shows significant regional variation, with North America leading due to high infection rates and robust healthcare infrastructure. The CDC estimates that C. difficile causes nearly 12,800 deaths annually in the U.S., making it a critical focus for public health initiatives. Europe follows closely, where the European Centre for Disease Prevention and Control (ECDC) has implemented strict infection control measures, including mandatory reporting of HAIs, which has spurred market growth. The Asia-Pacific region is witnessing rising awareness and improved diagnostic capabilities, particularly in countries like Japan and China. In 2021, Japan's Ministry of Health launched initiatives to reduce antimicrobial resistance, directly impacting the demand for CDI treatments. Latin America and the Middle East & Africa regions, though slower to adopt advanced therapies, are seeing increasing investments in healthcare, driven by rising infection rates and efforts to strengthen healthcare systems. These regions are gradually improving access to innovative treatments, creating future market potential.

Clostridium Difficile Infection Treatment Market- Competitive Landscape:

The Clostridium Difficile Infection Treatment Market is highly competitive, with key players focusing on strategic initiatives such as partnerships, acquisitions, and drug innovation. Leading companies like Merck & Co., Inc. and Ferring Pharmaceuticals are at the forefront of the market. Merck's DIFICID(R) (fidaxomicin) remains a leading treatment option, and in 2022, the company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to explore next-generation therapies. Ferring Pharmaceuticals made headlines with its acquisition of Rebiotix, Inc., accelerating its development of microbiome-based therapies, including the FDA-approved REBYOTA(R), a pioneering fecal microbiota transplant (FMT) therapy for CDI. Pfizer, too, is making strides, working on a C. difficile vaccine candidate that entered late-stage clinical trials in 2021. These strategic moves demonstrate how major players are not only competing but also collaborating to address the growing global burden of CDI, positioning themselves for future growth and innovation.

Recent Developments:

In April 2023, Seres Therapeutics and Nestle Health Science announced FDA approval for VOWST, the first orally administered microbiota-based therapy for preventing recurrent Clostridioides difficile infections in adults after antibacterial treatment. The product is expected to be available in June.

In May 2024, Acurx Pharmaceuticals announced a successful FDA End-of-Phase 2 meeting for ibezapolstat, confirming plans for international Phase 3 trials to treat C. difficile infection. The FDA approved the trial design and endpoints, paving the way for the submission of the New Drug Application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Acurx Pharmaceuticals, Inc.
  • Da Volterra
  • Ferring Pharmaceuticals Inc.
  • Finch Therapeutics Group, Inc.
  • Immuron Ltd.
  • Johnson & Johnson Services, Inc.
  • Maat Pharma SA
  • Merck & Co., Inc.
  • Microbiotica Ltd.
  • Pfizer Inc.
  • Prokaryotics Inc.
  • Rebiotix Inc. (a Ferring company)
  • Sanofi S.A.
  • Seres Therapeutics, Inc.
  • Summit Therapeutics plc
  • Vedanta Biosciences, Inc.
  • Others

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Antibiotics
  • Probiotics
  • Fecal Microbiota Transplantation (FMT)
  • Monoclonal Antibodies

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous
  • Rectal

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Long-Term Care Facilities
  • Homecare Settings

GLOBAL CLOSTRIDIUM DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridium Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridium Difficile Infection Treatment Market Snippet by Type
    • 2.1.2. Clostridium Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridium Difficile Infection Treatment Market Snippet by End-User
    • 2.1.4. Clostridium Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridium Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridium Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridium Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridium Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridium Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridium Difficile Infection Treatment Market Future Trends

4. Clostridium Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridium Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridium Difficile Infection Treatment Market Landscape

  • 6.1. Clostridium Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridium Difficile Infection Treatment Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Antibiotics
    • 7.1.3. Probiotics
    • 7.1.4. Fecal Microbiota Transplantation (FMT)
    • 7.1.5. Monoclonal Antibodies

8. Clostridium Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous
    • 8.1.4. Rectal

9. Clostridium Difficile Infection Treatment Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Clinics
    • 9.1.4. Long-Term Care Facilities
    • 9.1.5. Homecare Settings

10. Clostridium Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridium Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridium Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridium Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridium Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridium Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridium Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Acurx Pharmaceuticals, Inc.
    • 11.2.2. Da Volterra
    • 11.2.3. Ferring Pharmaceuticals Inc.
    • 11.2.4. Finch Therapeutics Group, Inc.
    • 11.2.5. Immuron Ltd.
    • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.7. Maat Pharma SA
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. Microbiotica Ltd.
    • 11.2.10. Pfizer Inc.
    • 11.2.11. Prokaryotics Inc.
    • 11.2.12. Rebiotix Inc. (a Ferring company)
    • 11.2.13. Sanofi S.A.
    • 11.2.14. Seres Therapeutics, Inc.
    • 11.2.15. Summit Therapeutics plc
    • 11.2.16. Vedanta Biosciences, Inc.
    • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us